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INTRODUCTION
Epilepsy is a chronic condition in which non-compliance is 
considered to be a significant problem faced during clinical 
treatment. Poor compliance to treatment is one of many 
reasons for pharmacological treatment failure and seizure 
recurrence. Despite all the best intention and efforts on 
the part of the healthcare professionals, those outcomes 
might not be achievable if the patients are non-compliant. 
(1) The behavior of compliance depends on specific clinical 
situation, nature of the illness, and treatment program. 
The effect of recurrent epileptic seizure attacks on the 
patient is far reaching. Poor compliance may lead to status 
epilepticus, as well as unexpected, sudden death. (2) 
Recurrent convulsions can reduce the likelihood of 
eventually curing the disorder. With appropriate treatment 
and lifestyle changes, the majority of patients diagnosed 
with epilepsy will become seizure-free. Compliant 
behaviour can be defined as taking anti-epileptic drugs 
(AEDs) on time and without fail, not manipulating dosages, 
and following the doctor’s advice regarding daily activities. 
(2) Non-compliance is a significant problem in epilepsy 
management. As many as 30 to 50% of persons with 
epilepsy are non-compliant to the extent of interfering with 
their optimal treatment. (2) The effect of non-compliance is 
enormous and may lead to an increase in the number of 
seizures, medical costs and injury to themselves and 
others.(2) The frequency of non-compliance was 19% in the 
outpatient group as reported in one study. (3) Reasons for 
non-compliance are complex and multilayered. Patients 
can accidentally fail to adhere through forgetfulness, 
misunderstanding, or uncertainty about clinician’s 
recommendations, or intentionally due to their own 
expectations of treatment, side-effects, and lifestyle 
choice. (3) In India, a study relating to doctor-patient 
communication and compliance stated that compliance 
improved when patients were satisfied with the 
consultation process and were asked to recall the 
information. Multiple visits to the doctor enhanced 
communication, and thus compliant behaviour. (4) Most of 
studies have attempted either to identify predictors or to 
measure the incidence of non-compliance but there is not 
a validated scale for measuring epilepsy patient 
non-compliance to antiepileptic drugs. This is especially 
true for developing countries including Pakistan. The lack 
of these measurements provides difficulties to assess the 
impact of specific factors in compliance to treatment. 
Services Hospital is the regional hospital in the central 
Punjab and serves a huge population of the country. There 
is scarcity of published data reporting the prevalence of 
epileptic patients with noncompliance of antiepileptic 
drugs. In the present study, we have aimed to determine 
the prevalence of compliance and non-compliance of 
antiepileptic drugs in epileptic patients. 
MATERIALS AND METHODS
The present study was conducted in OPD (Outpatient 
Department) at Services Institute of Medical Sciences and 
Services Hospital, Lahore, Pakistan. This 6-month 
descriptive study was carried out in 2012 and included a 
total of 225 patients who were admitted with the primary 
diagnosis of Epilepsy. Male and female patients aged 
between 10 to 70 years, who had been diagnosed with 
epilepsy at least one year previously, were included. 
Patients having other co-morbidities were excludded from 
this study. The data-collection tools were a questionnaire 
and a structured interview. Patients who were not able to 
respond to an interview were also excluded. For each 
patient detail history was taken including demographic 
information (age, sex, address) and questionnaire was 
asked after taking informed consent by researcher herself. 
All patients were observed for anti-epilepsy drug 
compliance and non-compliance. Patients included in 
study, were treated free of cost. Participants gave written 
informed consent after the purpose of the study had been 
explained to them. The ethics committee of the hospital 
approved the study. 
Statistical Analyses
The descriptive statistical analysis included examinations 
of means, standard deviations, frequencies, ranges, and 
percentages. The statistical packages SPSS (Version 20) 
and MS Excel (MS Office 2010) were used. 
RESULTS
A total of 225 patients fulfilling the inclusion criteria were 
enrolled to measure the frequency of noncompliance of 
antiepileptic drugs in epileptic patients. Age distribution of 
the patients was done which showed that 29.78% 
(n=67) were between 10-30 years, 36% (n=81) 
between 41-55 years and 34.22% (n=77) were between 
56-70 years of age. Average age of the patients was 
46.87+5.23 years (Table 1). 
Table 1. Age distribution of patients included in the study.
Mean and SD: 46.87+5.23 (n= 225)
Gender distribution of the patients showed that 59.6% 
(n=134) were males and 40.4% (n=91) were females 
(Table 2). 
Table 2. Gender distribution of all patients included in this 
study.
Results regarding the frequency of epileptic patients with 
compliance and non-compliance of antiepileptic drugs 
have been shown in Figure 1. Figure shows that out of 
225 patients, 172 patients (76.4%) had compliance of 
antiepileptic drugs. Whereas 53 patients (23.6%) showed 
non-compliance to antiepileptic drugs (Figure 1).
 
Figure 1. Frequency of compliance and non-compliance 
of antiepileptic drugs among epileptic patients.
We also identified the gender distribution of epileptic 
patients with non-compliance of antiepileptic drugs. The 
results have been shown in Table 3 which shows that out 
of 53 cases of non-compliance, 33 cases (62.3%) were 
male and 20 cases (37.7%) were females (Table 3). This 
finding showed that incidence of non-compliance was 
more frequent in males as compared to females.
Table 3. Stratification for noncompliance of antiepileptic 
drugs in epileptic patients with regards to gender.
 (n=53)
 
DISCUSSION
The sole treatment available for the majority of patients 
with epilepsy is antiepileptic drug (AED) therapy. Research 
has shown that missing or altering antiepileptic drug 
dosages can have adverse reactions, that is, increase the 
chance of seizure recurrence. For instance, Mattson et al. 
reported that over one quarter of seizures occurred at or 
before reports of inadequate medication levels. Failure to 
follow prescribed drug regimens is known to be fairly 
widespread amongst patients with epilepsy: research has 
shown that between 25 and 75% fail to adhere, in 
particular very young or very old patients, and teenagers. 
Given that failing to comply may increase the likelihood of 
hospital admission, there could be a potential savings if 
compliance could be improved. We planned this study to 
determine the most prevalent factors in Pakistan because 
demographic, psychosocial, economic factors, literacy 
rate is different. Non-compliance of antiepileptic drugs in 
epileptic patients leads to recurrent seizures, thus mental 
regression occurs (2); by knowing the frequency of 
non-compliance, we can adopt some strategies to 
over-come this problem to improve levels of compliance 
thereby reducing the risk of unnecessary seizures. In this 
study, frequency of non-compliance of antiepileptic drugs 
in epileptic patients was revealed in 23.56% while 
76.44% had no complaint of non-compliance. The 
findings of the present study regarding frequency of 
non-compliance are in agreement with Hauser et al. (5) 
WHO reported that 19% of the patients had 
non-compliance in the outpatient group.(5) The evidence 
indicates that non-compliance is still common in 
healthcare and no substantial change occurred despite 
the large number of studies attempting to address and 
highlight the problem. In addition, too few studies are 
being done systematically to quantify the impact of 
non-compliance on health and financial outcomes. The 
magnitude of the impact of non-compliance needs to be 
studied in future compliance research due to the potential 
tremendous implication of poor compliance on clinical 
and economic outcomes.
CONCLUSION
We concluded that the frequency of noncompliance of 
antiepileptic drugs among epileptic patients is higher. This 
condition is worsening for males since they showed a 
greater percentage of non-compliance as compared to 
females. This situation needs special attention of the 
physicians while managing epileptic patients.
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ABSTRACT
Objective: To assess the efficacy of memantine as a preventive and therapeutic intervention for migraine and tension 
type headache. Material and Methods: This quasi experimental (pre and post experimental) was conducted for a period 
of 6 months. Patients were selected from a private tertiary care hospital setup a total of 44 patients receiving memantine, 
were selected through purposive sampling technique. Data was analysed using SPSS version 16.0 and associations were 
made using Chi square test with P value of less than 0.005 was taken as significant. Results: Out of 44 patients 35 
(79.9%) were female and 9 (20.5%) were male which shows a very high occurrence of migraine and tension type 
headaches in females. Average age was found to be 32.6% Efficacy of the drug was observed to be 81.8% which is 
significantly high. The baseline MIDAS score when compared with score at 3 months follow up by applying Wilcoxon 
signed rank test showed mean ± S.D (39.52±21.27 vs. 6.72±6.41) where p=0.000 ≤0.005 which shows highly 
significant results. All 44 patients were known cases of migraine while 25% of them also suffered from tension type 
headache. Patients were treated on 10 mg dose of memantinea and were observed for the efficacy of the drug. Patients 
maintained their diaries of intensity of pain, distressing influence of pain and how it hindered their daily routine. Results 
show that intensity of pain fell significantly by the end of 3rd month of treatment while majority of the patients felt less 
distressed on their final follow up.  By the end of the 3rd month the level of hindrance caused by the migraine pain in the 
daily routines of the patients also fell significantly. Conclusion: Memantine is effective as a preventive and therapeutic 
intervention for migraine and tension type headache.
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EFFICACY OF MEMANTINE AS A PREVENTIVE AND
THERAPEUTIC INTERVENTION FOR MIGRAINE AND
TENSION TYPE HEADACHE
INTRODUCTION
Memantine, an N-methyl D-aspartate (NMDA) receptor 
antagonist, works through its intrinsic blockade of afferent 
signals of pain transmission , known as the glutamate 
system, which is plays a major role in pathophysiology of 
tension type headaches (TTH) and migraine1. Memantine 
works as an uncompetitive low affinity open channel 
antagonist. Most importantly its dissociation rate is 
relatively faster so that it doe not accumulate in the 
synaptic channels hence does not interfere with normal 
synaptic transmission2,3. Thence can be used as an 
effective modality in prophylaxis and treatment for chronic 
pain disorders including chronic headaches and migraine.
During the recent decade memantine has evolved as an 
revolutionary drug in treatment of chronic pain states4. Its 
efficacy as a neuroprotective drug has been demonstrated 
through various researches5. Studies have proven that 
menantine has its excellent effects on D2 receptors as 
well preventing its sensitization during a manic attack 
hence can be used as drug of choice for bipolar disorder.6  
Recent works are being done to evaluate it effectiveness  
in demented disorders  such as Alzhiemers7. The 
aforementioned wide variety of uses in the field of 
medicine has greatly increased the interest of researchers 
in this revolutionary drug. Our area of interest is to find out 
efficacy of memantine in prophylaxis and  treatment of 
migraine and tension type headaches as marked  by 
decrease in frequency and increase in patients self 
reporting of symptomatology.
METHODS
This quasi experimental (pre and post experimental) was 
conducted in the year 2014 for time duration of 6 months 
. Patients were selected in a private setup tertiary care 
hospital . All statistical analyses were done using SPSS 
software version 16.0. A sample of 44 was calculated for 
this study by taking a confidence interval of 5 while 95% 
confidence level was considered with p≤0.005.
Inclusion Criteria:
All patients known to have migraine for more than 1 year 
INTRODUCTION
Epilepsy is a chronic condition in which non-compliance is 
considered to be a significant problem faced during clinical 
treatment. Poor compliance to treatment is one of many 
reasons for pharmacological treatment failure and seizure 
recurrence. Despite all the best intention and efforts on 
the part of the healthcare professionals, those outcomes 
might not be achievable if the patients are non-compliant. 
(1) The behavior of compliance depends on specific clinical 
situation, nature of the illness, and treatment program. 
The effect of recurrent epileptic seizure attacks on the 
patient is far reaching. Poor compliance may lead to status 
epilepticus, as well as unexpected, sudden death. (2) 
Recurrent convulsions can reduce the likelihood of 
eventually curing the disorder. With appropriate treatment 
and lifestyle changes, the majority of patients diagnosed 
with epilepsy will become seizure-free. Compliant 
behaviour can be defined as taking anti-epileptic drugs 
(AEDs) on time and without fail, not manipulating dosages, 
and following the doctor’s advice regarding daily activities. 
(2) Non-compliance is a significant problem in epilepsy 
management. As many as 30 to 50% of persons with 
epilepsy are non-compliant to the extent of interfering with 
their optimal treatment. (2) The effect of non-compliance is 
enormous and may lead to an increase in the number of 
seizures, medical costs and injury to themselves and 
others.(2) The frequency of non-compliance was 19% in the 
outpatient group as reported in one study. (3) Reasons for 
non-compliance are complex and multilayered. Patients 
can accidentally fail to adhere through forgetfulness, 
misunderstanding, or uncertainty about clinician’s 
recommendations, or intentionally due to their own 
expectations of treatment, side-effects, and lifestyle 
choice. (3) In India, a study relating to doctor-patient 
communication and compliance stated that compliance 
improved when patients were satisfied with the 
consultation process and were asked to recall the 
information. Multiple visits to the doctor enhanced 
communication, and thus compliant behaviour. (4) Most of 
studies have attempted either to identify predictors or to 
measure the incidence of non-compliance but there is not 
a validated scale for measuring epilepsy patient 
non-compliance to antiepileptic drugs. This is especially 
true for developing countries including Pakistan. The lack 
of these measurements provides difficulties to assess the 
impact of specific factors in compliance to treatment. 
Services Hospital is the regional hospital in the central 
Punjab and serves a huge population of the country. There 
is scarcity of published data reporting the prevalence of 
epileptic patients with noncompliance of antiepileptic 
drugs. In the present study, we have aimed to determine 
the prevalence of compliance and non-compliance of 
antiepileptic drugs in epileptic patients. 
MATERIALS AND METHODS
The present study was conducted in OPD (Outpatient 
Department) at Services Institute of Medical Sciences and 
Services Hospital, Lahore, Pakistan. This 6-month 
descriptive study was carried out in 2012 and included a 
total of 225 patients who were admitted with the primary 
diagnosis of Epilepsy. Male and female patients aged 
between 10 to 70 years, who had been diagnosed with 
epilepsy at least one year previously, were included. 
Patients having other co-morbidities were excludded from 
this study. The data-collection tools were a questionnaire 
and a structured interview. Patients who were not able to 
respond to an interview were also excluded. For each 
patient detail history was taken including demographic 
information (age, sex, address) and questionnaire was 
asked after taking informed consent by researcher herself. 
All patients were observed for anti-epilepsy drug 
compliance and non-compliance. Patients included in 
study, were treated free of cost. Participants gave written 
informed consent after the purpose of the study had been 
explained to them. The ethics committee of the hospital 
approved the study. 
Statistical Analyses
The descriptive statistical analysis included examinations 
of means, standard deviations, frequencies, ranges, and 
percentages. The statistical packages SPSS (Version 20) 
and MS Excel (MS Office 2010) were used. 
RESULTS
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enrolled to measure the frequency of noncompliance of 
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(n=67) were between 10-30 years, 36% (n=81) 
between 41-55 years and 34.22% (n=77) were between 
56-70 years of age. Average age of the patients was 
46.87+5.23 years (Table 1). 
Table 1. Age distribution of patients included in the study.
Mean and SD: 46.87+5.23 (n= 225)
Gender distribution of the patients showed that 59.6% 
(n=134) were males and 40.4% (n=91) were females 
(Table 2). 
Table 2. Gender distribution of all patients included in this 
study.
Results regarding the frequency of epileptic patients with 
compliance and non-compliance of antiepileptic drugs 
have been shown in Figure 1. Figure shows that out of 
225 patients, 172 patients (76.4%) had compliance of 
antiepileptic drugs. Whereas 53 patients (23.6%) showed 
non-compliance to antiepileptic drugs (Figure 1).
 
Figure 1. Frequency of compliance and non-compliance 
of antiepileptic drugs among epileptic patients.
We also identified the gender distribution of epileptic 
patients with non-compliance of antiepileptic drugs. The 
results have been shown in Table 3 which shows that out 
of 53 cases of non-compliance, 33 cases (62.3%) were 
male and 20 cases (37.7%) were females (Table 3). This 
finding showed that incidence of non-compliance was 
more frequent in males as compared to females.
Table 3. Stratification for noncompliance of antiepileptic 
drugs in epileptic patients with regards to gender.
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demographic, psychosocial, economic factors, literacy 
rate is different. Non-compliance of antiepileptic drugs in 
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of duration and at least one migraine attack per month 
were included in the study. All patients above 15 years 
and below 65 years of age were included in the study. 
Exclusion Criteria:
Patients on any other drug are not to be considered. 
Table 1: baseline characteristic
The proforma was well explained and self interviewed . Out 
of 44 patients, gender distribution of Male = 9 (20.5%) and  
Female= 35 (79.5%) . with chronic migraine and tension 
type headache were studied. At baseline , study patients 
were on regular memantine. We added memantine, 5mg 
per day with weekly increases of 5mg (up to a maximum of 
20mg per day), as tolerated. The average dose of 
memantine was 19.25mg per day across all study patients 
and ranged from 10 to 20mg. Patients kept headache 
diaries for migraines and TTH, as well as pain scores. 
Evaluations were conducted after one month of therapy for 
those being treated with 20mg dose of memantine. For 
those on a lesser, maximally tolerated dose of memantine, 
evaluations were conducted after at least 1.5 to 2 months’ 
therapy. The average length of treatment, including the 
initial titration of memantine dosage, was 6 months, with an 
average daily dosage of 19.25mg (ranging from 10 to 
20mg/day). Dose of menantine was increased for acute 
migraine attacks management. For descriptive stasitics 
frequency and percentages were calculated while 
association was made using chi square.
RESULTS
All statistical analyses were done using SPSS software 
version 16.0. A sample of 44 was calculated for this study 
by taking a confidence interval of 5 while 95% confidence 
level was considered with p≤0.005.
Figure: 1
All 44 patients were known cases of migraine while 25% 
of them also suffered from tension type headache as 
shown in table 1. Patients were treated on 10 mg dose of 
memantine and were observed for the efficacy of the 
drug. Patients maintained their diaries of intensity of pain, 
distressing influence of pain and how it hindered their 
daily routine.
Table 2: Frequency of pain intensity, distress and 
interference at baseline and after 3 months follow up
Variable Frequency (%) 
How intense is your pain now? 
Moderate pain 
Severe pain 
Extreme pain 
 
4 (9.1%) 
15(34.1%) 
25(56.8%) 
How intense was your pain on average last week? 
Moderate pain 
Severe pain 
Extreme pain 
 
13 (29.5%) 
15 (34.1%) 
16 (36.4%) 
How distressing is your pain now? 
Mild 
Moderate 
Severe 
Extreme 
 
2 (4.5%) 
6 (13.6%) 
25 (56.8%) 
11 (25%) 
How distressing was your pain on the average last 
week? 
Mild 
Moderate 
Severe 
Extreme  
 
3 (6.8%)  
7 (15.9%) 
25 (56.8%) 
9 (20.5%) 
How your pain interferes with your normal 
routines? 
Mild 
Moderate 
Severe 
Extreme 
 
1 (2.3%) 
12 (27.3%) 
26 (59.1%) 
5 (11.4%) 
At 3 months follow up: 
How intense is your pain now? 
No pain 
Mild 
Moderate 
Severe 
Extreme 
 
 
1 (2.3%) 
15 (34.1%) 
19 (43.2%) 
8 (18.2%) 
1 (2.3%) 
At 3 months follow up: 
How intense was your pain on the average last 
week? 
No pain 
Mild 
Moderate 
Severe 
Extreme 
 
 
 
1 (2.3%) 
11 (25%) 
18 (40.9%) 
13 (29.5%) 
1 (2.3%) 
At 3 months follow up: 
How distressing is your pain now? 
No distress 
Mild 
Moderate 
Severe 
Extreme 
 
 
3 (6.8%) 
14 (31.8%) 
20 (45.5%) 
6 (13.6%) 
1 (2.3%) 
At 3 months follow up: 
How distressing was your pain on the average last 
 
 
Variable Frequency 
(%) 
Mean ± S.D Range(Min/max) 
Gender 
Male 
Female 
 
9 (20.5%) 
35 
(79.5%) 
  
Age 
 
 32.6±10.32 15/65 
Efficacy 36 
(81.8%) 
  
Diagnosis 
migraine 
migraine+TTH 
migraine changing to seizures 
others 
 
20 
(45.45%) 
11 (25%) 
3 (6.81%) 
10 
(22.7%) 
  
Missed work or school (no. of days) 
 
 6.81±7.15 0/30 
Productivity at work/school reduced 
by half 
 6.88±5.52 0/20 
Could not perform household 
chores 
 9.97±6.36 0/33 
Productivity reduced by half in 
household work 
 10.52±6.06 3/32 
Missed leisure activities  5.86±4.84 0/20 
Average headache days  14.39±6.41 1/32 
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recurrence. Despite all the best intention and efforts on 
the part of the healthcare professionals, those outcomes 
might not be achievable if the patients are non-compliant. 
(1) The behavior of compliance depends on specific clinical 
situation, nature of the illness, and treatment program. 
The effect of recurrent epileptic seizure attacks on the 
patient is far reaching. Poor compliance may lead to status 
epilepticus, as well as unexpected, sudden death. (2) 
Recurrent convulsions can reduce the likelihood of 
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drugs. In the present study, we have aimed to determine 
the prevalence of compliance and non-compliance of 
antiepileptic drugs in epileptic patients. 
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Patients having other co-morbidities were excludded from 
this study. The data-collection tools were a questionnaire 
and a structured interview. Patients who were not able to 
respond to an interview were also excluded. For each 
patient detail history was taken including demographic 
information (age, sex, address) and questionnaire was 
asked after taking informed consent by researcher herself. 
All patients were observed for anti-epilepsy drug 
compliance and non-compliance. Patients included in 
study, were treated free of cost. Participants gave written 
informed consent after the purpose of the study had been 
explained to them. The ethics committee of the hospital 
approved the study. 
Statistical Analyses
The descriptive statistical analysis included examinations 
of means, standard deviations, frequencies, ranges, and 
percentages. The statistical packages SPSS (Version 20) 
and MS Excel (MS Office 2010) were used. 
RESULTS
A total of 225 patients fulfilling the inclusion criteria were 
enrolled to measure the frequency of noncompliance of 
antiepileptic drugs in epileptic patients. Age distribution of 
the patients was done which showed that 29.78% 
(n=67) were between 10-30 years, 36% (n=81) 
between 41-55 years and 34.22% (n=77) were between 
56-70 years of age. Average age of the patients was 
46.87+5.23 years (Table 1). 
Table 1. Age distribution of patients included in the study.
Mean and SD: 46.87+5.23 (n= 225)
Gender distribution of the patients showed that 59.6% 
(n=134) were males and 40.4% (n=91) were females 
(Table 2). 
Table 2. Gender distribution of all patients included in this 
study.
Results regarding the frequency of epileptic patients with 
compliance and non-compliance of antiepileptic drugs 
have been shown in Figure 1. Figure shows that out of 
225 patients, 172 patients (76.4%) had compliance of 
antiepileptic drugs. Whereas 53 patients (23.6%) showed 
non-compliance to antiepileptic drugs (Figure 1).
 
Figure 1. Frequency of compliance and non-compliance 
of antiepileptic drugs among epileptic patients.
We also identified the gender distribution of epileptic 
patients with non-compliance of antiepileptic drugs. The 
results have been shown in Table 3 which shows that out 
of 53 cases of non-compliance, 33 cases (62.3%) were 
male and 20 cases (37.7%) were females (Table 3). This 
finding showed that incidence of non-compliance was 
more frequent in males as compared to females.
Table 3. Stratification for noncompliance of antiepileptic 
drugs in epileptic patients with regards to gender.
 (n=53)
 
DISCUSSION
The sole treatment available for the majority of patients 
with epilepsy is antiepileptic drug (AED) therapy. Research 
has shown that missing or altering antiepileptic drug 
dosages can have adverse reactions, that is, increase the 
chance of seizure recurrence. For instance, Mattson et al. 
reported that over one quarter of seizures occurred at or 
before reports of inadequate medication levels. Failure to 
follow prescribed drug regimens is known to be fairly 
widespread amongst patients with epilepsy: research has 
shown that between 25 and 75% fail to adhere, in 
particular very young or very old patients, and teenagers. 
Given that failing to comply may increase the likelihood of 
hospital admission, there could be a potential savings if 
compliance could be improved. We planned this study to 
determine the most prevalent factors in Pakistan because 
demographic, psychosocial, economic factors, literacy 
rate is different. Non-compliance of antiepileptic drugs in 
epileptic patients leads to recurrent seizures, thus mental 
regression occurs (2); by knowing the frequency of 
non-compliance, we can adopt some strategies to 
over-come this problem to improve levels of compliance 
thereby reducing the risk of unnecessary seizures. In this 
study, frequency of non-compliance of antiepileptic drugs 
in epileptic patients was revealed in 23.56% while 
76.44% had no complaint of non-compliance. The 
findings of the present study regarding frequency of 
non-compliance are in agreement with Hauser et al. (5) 
WHO reported that 19% of the patients had 
non-compliance in the outpatient group.(5) The evidence 
indicates that non-compliance is still common in 
healthcare and no substantial change occurred despite 
the large number of studies attempting to address and 
highlight the problem. In addition, too few studies are 
being done systematically to quantify the impact of 
non-compliance on health and financial outcomes. The 
magnitude of the impact of non-compliance needs to be 
studied in future compliance research due to the potential 
tremendous implication of poor compliance on clinical 
and economic outcomes.
CONCLUSION
We concluded that the frequency of noncompliance of 
antiepileptic drugs among epileptic patients is higher. This 
condition is worsening for males since they showed a 
greater percentage of non-compliance as compared to 
females. This situation needs special attention of the 
physicians while managing epileptic patients.
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 Results in table 1 show that intensity of pain fell 
significantly by the end of 3rd month of treatment while 
majority of the patients felt less distressed on their final 
follow up.  By the end of the 3rd month the level of 
hindrance caused by the migraine pain in the daily 
routines of the patients also fell significantly. Out of 44 
patients 35 (79.9%) were female and 9 (20.5%) were 
male which shows a very high occurrence of migraine and 
tension type headaches in females. Average age was 
found to be 32.6% Efficacy of the drug was observed to be 
81.8% which is significantly high, only 20% of the patients 
required the increment of 5mg in the prior adjusted dose. 
The baseline MIDAS score when compared with score at 
3 months follow up by applying Wilcoxon signed rank test 
showed mean ± S.D (39.52±21.27 vs. 6.72±6.41) 
where p=0.000 ≤0.005 which shows highly significant 
result (as shown in fig:2). 
 
Table 3: Comparison of baseline scores with follow up 
after 3 months
 
Figure:1
DISCUSSION
This study sought to explain the efficacy of memantine in 
the prevention and treatment of migraine and tension 
type headache. Studies have elucilated that memantine 
works by blocking N-methyl-D-aspartate (NMDA) 
glutamate receptors that are excitatory amino acids , play 
an intrinsic role in pain transmission,long-term 
potentiation and central sensitization. Therefore, blockade 
of NMDA helps in reducing the central barrage of afferent 
signals that might contribute to maintenance of migraine 
states. Agents whose activity, in part, impinges on the 
glutamate system are already in use for migraine 
prophylaxis1 As compared to other similar researches the 
participants mainly comprised of females proving a 
worldwide female dominance in incidence of chronic 
migraine and tension type headache7,1. Our subjects were 
classified according to the type and nature of chronic 
tension headache. Comprising of migraine alone, 
migraine along with tension type headache, migraine 
changing to seizures and others in coherence to other 
researches8. An initial dose of 10mg memantine was 
started and the patients were asked to maintain a 
headache diary so this helps in keeping proper record and 
effectiveness of drug in every individual patients.9. As per 
patients self reporting in their headache diary the 
interference of pain with routine work markedly reduces in 
frequency from 59% to 40% (p<0.005). this was 
observed in other researches headache frequency was 
reduced from 21.8 days at baseline to 16.1 (P < .01) at 
3 months10. When patients reported after 3 months 
follow up there was a significant reduction in frequency of 
occurrence of symptoms, statistically proven as 
39.52±21.27 vs. 6.72±6.41 (baseline vs  follow up). 
CONCLUSION 
Memantine is effective as a preventive and therapeutic 
intervention for migraine and tension type headache.
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